|Dr. Peter A. Altman Ph.D.||CEO, Pres & Director||488.06k||N/A||1967|
|Mr. David McClung||Chief Financial Officer||364.31k||N/A||1963|
|Mr. Edward M. Gillis||Sr. VP of Devices||267.79k||N/A||1962|
|Dr. Ian McNiece Ph.D.||Chief Scientific Officer||N/A||N/A||1954|
|Dr. Sujith Shetty||Chief Medical Officer and VP of Clinical & Regulatory||N/A||N/A||N/A|
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.